
    
      Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin
      + Docetaxel in patients with metastatic breast cancer. Patients will receive pyridoxin to
      prevent cutaneo-mucinous toxicities.
    
  